Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Not yet recruiting
National Cancer Institute (NCI)
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating
patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant
protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors
on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401
with chemotherapy may be an effective treatment for patients with blastic plasmacytoid
dendritic cell neoplasm.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.